Systemic therapy for recurrent endometrial cancer: a review of North American trials.

Abstract

While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.

DOI: 10.1586/era.09.54
05010020102011201220132014201520162017
Citations per Year

268 Citations

Semantic Scholar estimates that this publication has 268 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Dellinger2009SystemicTF, title={Systemic therapy for recurrent endometrial cancer: a review of North American trials.}, author={Thanh H. Dellinger and Bradley J. Monk}, journal={Expert review of anticancer therapy}, year={2009}, volume={9 7}, pages={905-16} }